Sanofi announced a definitive agreement to acquire Blueprint Medicines Corporation, a U.S.-based biopharmaceutical company focused on systemic mastocytosis (SM) and other KIT-driven diseases. This...
Blueprint Medicines Corporation announced AYVAKIT data showing high, durable response rates and prolonged overall survival (OS) in patients with advanced systemic mastocytosis (Advanced SM),...
